Wedbush initiated coverage of MoonLake Immunotherapeutics with an Outperform rating and $33 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MLTX:
- This Insider Just Pocketed MoonLake (NASDAQ:MLTX) Stock Worth $16.8M
- MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
- MoonLake Immunotherapeutics sees cash runway into 2H24
- MoonLake Immunotherapeutics announces upcoming 2023 milestones
- MoonLake Immunotherapeutics reports Q4 EPS (31c), consensus (33c)